Cargando…
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
OBJECTIVE: To estimate the cost-effectiveness of adalimumab plus methotrexate (MTX) versus MTX monotherapy in early, aggressive rheumatoid arthritis (RA) when explicitly modelling short-term (reversible) and long-term (irreversible, ie, joint damage) disease activity and physical function. METHODS:...
Autores principales: | Stephens, Stephanie, Botteman, Marc F, Cifaldi, Mary A, van Hout, Ben A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466612/ https://www.ncbi.nlm.nih.gov/pubmed/26059521 http://dx.doi.org/10.1136/bmjopen-2014-006560 |
Ejemplares similares
-
Biomarkers in Rheumatoid Arthritis
por: Shapiro, Samantha C
Publicado: (2021) -
Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021) -
Prevalence and Severity of Temporomandibular Disorders in Rheumatoid Arthritis Patients
por: Mustafa, Mohammad A, et al.
Publicado: (2022) -
Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis
por: Nazir, Armaan M, et al.
Publicado: (2021) -
Biological tapering and sonographic flare in rheumatoid arthritis
por: Ko, Chi-Hua, et al.
Publicado: (2018)